NCT05555238View on ClinicalTrials.gov

An Observational Study to Evaluate the Treatment of Newvast® Tab(Atorvastatin) in Korean Patients With Dyslipidemia

CompletedOBSERVATIONAL
Enrollment

1,716

Participants

Timeline

Start Date

January 16, 2020

Primary Completion Date

January 27, 2022

Study Completion Date

January 27, 2022

Conditions
Dyslipidemia
Interventions
DRUG

single arm, single group(No interventional)

(Newvast® Tab, 10 to 80 mg daily administered per the locally approved product information)

Trial Locations (1)

05545

Hanmi Pharmaceutical Company Limited, Seoul

Sponsors
All Listed Sponsors
lead

Hanmi Pharmaceutical Company Limited

INDUSTRY

NCT05555238 - An Observational Study to Evaluate the Treatment of Newvast® Tab(Atorvastatin) in Korean Patients With Dyslipidemia | Biotech Hunter | Biotech Hunter